Literature DB >> 24099053

Treatment of convulsive status epilepticus in childhood: recommendations of the Italian League Against Epilepsy.

Giuseppe Capovilla1, Francesca Beccaria, Ettore Beghi, Fabio Minicucci, Stefano Sartori, Marilena Vecchi.   

Abstract

The Italian League Against Epilepsy Commission Guidelines Subcommittee on Status Epilepticus (SE) has published an article on the management of SE in adults, and now presents a report on the management of convulsive status epilepticus (CSE) in children, excluding the neonatal period. Children's greater susceptibility than adults to epileptic seizures results from many factors. Earlier maturation of excitatory than inhibitory synapses, increased susceptibility and concentration of receptors for excitatory neurotransmitters, peculiar composition of the receptor subunits resulting in slower and less effective inhibitory responses, all cause the high incidence of SE in the pediatric population. The related morbidity and mortality rates, although lower than in adults, require immediate diagnosis and therapy. The division into focal and generalized, nonconvulsive and convulsive SE is applied in children and adolescents, as is the distinction in the three different stages according to the time elapsed since the start of the event and the response to drugs (initial, defined, and refractory SE). In children and adolescents, an "operational definition" is also accepted to allow earlier treatment (starting at 5-10 min). Maintenance and stabilization of vital functions, cessation of convulsions, diagnosis, and initial treatment of potentially "life-threatening" causes are the objectives to be pursued in the management of children with CSE. The need for early pharmacologic intervention stresses the need for action in the prehospital setting, generally using rectal diazepam. In hospital, parenteral benzodiazepines are used (lorazepam, diazepam, or midazolam). When first-line drugs fail, sodium phenytoin and phenobarbital should be used. As alternatives to phenobarbital, the following can be considered for treatment of refractory CSE: valproate, levetiracetam, and lacosamide. In cases with refractory CSE, pharmacologic options can be thiopental, midazolam, or propofol in continuous intravenous infusions to suppress electroencephalographic bursts and convulsive activity. These drugs need to be administered in intensive care units to ensure the monitoring and support of vital signs and brain electrical activity. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  Epileptic status; Treatment

Mesh:

Substances:

Year:  2013        PMID: 24099053     DOI: 10.1111/epi.12307

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  15 in total

Review 1.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

2.  Efficacy of nonvenous medications for acute convulsive seizures: A network meta-analysis.

Authors:  Ravindra Arya; Harsh Kothari; Zongjun Zhang; Baoguang Han; Paul S Horn; Tracy A Glauser
Journal:  Neurology       Date:  2015-10-28       Impact factor: 9.910

3.  Time from convulsive status epilepticus onset to anticonvulsant administration in children.

Authors:  Iván Sánchez Fernández; Nicholas S Abend; Satish Agadi; Sookee An; Ravindra Arya; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Tracy A Glauser; Howard P Goodkin; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Margie Ream; James Riviello; Robert C Tasker; Tobias Loddenkemper
Journal:  Neurology       Date:  2015-05-06       Impact factor: 9.910

4.  Changes of biochemical biomarkers in the serum of children with convulsion status epilepticus: a prospective study.

Authors:  Manli Wang; Jian Yu; Xiao Xiao; Bingbing Zhang; Jihong Tang
Journal:  BMC Neurol       Date:  2022-05-27       Impact factor: 2.903

5.  Efficacy, Safety, and Economics of Intravenous Levetiracetam for Status Epilepticus: A Systematic Review and Meta-Analysis.

Authors:  Zhan-Miao Yi; Xu-Li Zhong; Ming-Lu Wang; Yuan Zhang; Suo-Di Zhai
Journal:  Front Pharmacol       Date:  2020-05-21       Impact factor: 5.810

Review 6.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

7.  Enteral topiramate in a pediatric patient with refractory status epilepticus: a case report and review of the literature.

Authors:  Chasity M Shelton; Elizabeth L Alford; Stephanie Storgion; James Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

8.  Super-Refractory Status Epilepticus: A Therapeutic Challenge in Paediatrics.

Authors:  Shrikiran Aroor; Kanaparthi Shravan; Suneel C Mundkur; C Jayakrishnan; Sai Sripad Rao
Journal:  J Clin Diagn Res       Date:  2017-08-01

9.  Complications during the management of pediatric refractory status epilepticus with benzodiazepine and pentobarbital infusions.

Authors:  Mahmood Dhahir Al-Mendalawi
Journal:  Indian J Crit Care Med       Date:  2015-07

Review 10.  Management of acute seizures in children: A review with special consideration of care in resource-limited settings.

Authors:  Ornella Ciccone; Manoj Mathews; Gretchen L Birbeck
Journal:  Afr J Emerg Med       Date:  2017-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.